Published in PLoS One on March 07, 2011
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS One (2013) 1.09
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res (2013) 0.84
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis (2013) 0.80
High content image based analysis identifies cell cycle inhibitors as regulators of Ebola virus infection. Viruses (2012) 0.80
Workflow for high-content, individual cell quantification of fluorescent markers from universal microscope data, supported by open source software. J Vis Exp (2014) 0.75
Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. Mol Cancer Ther (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82
CDK inhibitors: cell cycle regulators and beyond. Dev Cell (2008) 5.07
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol (2009) 4.09
Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell (2008) 4.01
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol (2009) 3.48
Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell (2008) 3.38
Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol (2004) 3.29
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev (1996) 3.26
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev (1996) 2.81
Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell (2006) 2.62
Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol (2007) 2.54
Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci (2003) 2.48
Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem (2004) 2.37
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res (2005) 2.24
Human MPS1 kinase is required for mitotic arrest induced by the loss of CENP-E from kinetochores. Mol Biol Cell (2003) 2.08
Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res (2009) 1.96
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem (2003) 1.80
Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell (2006) 1.71
The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol (1998) 1.62
To cell cycle, swing the APC/C. Biochim Biophys Acta (2008) 1.60
Heat shock protein 90: inhibitors in clinical trials. J Med Chem (2010) 1.57
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
17 AAG for HSP90 inhibition in cancer--from bench to bedside. Curr Mol Med (2009) 1.40
Hsp90 activation and cell cycle regulation. Cell Cycle (2004) 1.40
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene (2007) 1.38
Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem (1997) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
H3 phosphorylation: dual role in mitosis and interphase. Biochem Cell Biol (2009) 1.30
Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol (2000) 1.28
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res (2000) 1.26
Molecular dissection of the centrosome overduplication pathway in S-phase-arrested cells. Mol Cell Biol (2009) 1.24
Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates. EMBO J (2000) 1.23
HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle (2008) 1.22
Death by chaperone: HSP90, HSP70 or both? Cell Cycle (2009) 1.22
Hsp90-Sgt1 and Skp1 target human Mis12 complexes to ensure efficient formation of kinetochore-microtubule binding sites. J Cell Biol (2010) 1.15
17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation. Oncogene (2006) 1.12
Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry (2005) 1.12
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol (2005) 1.11
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene (2007) 1.11
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res (2006) 1.10
Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res (2004) 1.08
Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene (2007) 1.08
Sgt1, a co-chaperone of Hsp90 stabilizes Polo and is required for centrosome organization. EMBO J (2009) 1.06
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol (2006) 1.04
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res (1996) 1.01
Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol (2007) 0.98
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol (2008) 0.98
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol (2008) 0.96
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Mol Cancer Ther (2008) 0.94
HSP90: a rising star on the horizon of anticancer targets. Future Oncol (2005) 0.92
Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene (2008) 0.92
HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs (2007) 0.90
Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells. Cell Cycle (2008) 0.89
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene (2007) 0.89
Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer. Nat Chem Biol (2007) 0.88
Check, double check: the G2 barrier to cancer. Cell Cycle (2006) 0.86
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol (2007) 0.85
Hsp90 is required to localise cyclin B and Msps/ch-TOG to the mitotic spindle in Drosophila and humans. J Cell Sci (2007) 0.85
Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem (2004) 0.84
A novel role for Cdk1/cyclin B in regulating B-raf activation at mitosis. Mol Biol Cell (2008) 0.81
A bitter PP1 fights the sweet polo. Mol Cell (2008) 0.77
Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol (2003) 10.10
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Structural basis of mitochondrial tethering by mitofusin complexes. Science (2004) 4.21
Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell (2008) 3.72
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol (2006) 2.39
A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet (2003) 2.29
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther (2003) 2.07
Hedgehog signal transduction via Smoothened association with a cytoplasmic complex scaffolded by the atypical kinesin, Costal-2. Mol Cell (2003) 2.02
Retracted IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J (2002) 1.94
Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. Cell (2002) 1.77
Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology (2002) 1.64
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J (2013) 1.47
A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res (2002) 1.46
LET-99 determines spindle position and is asymmetrically enriched in response to PAR polarity cues in C. elegans embryos. Development (2002) 1.44
Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle (2007) 1.40
MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun (2002) 1.39
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res (2013) 1.38
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas (2003) 1.30
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res (2008) 1.30
A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem (2003) 1.20
Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics (2002) 1.16
Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice. Endocrinology (2002) 1.13
p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res (2006) 1.13
Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B. J Biol Chem (2002) 1.11
TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem (2005) 1.08
Site-specific hydration dynamics in the nonpolar core of a molten globule by dynamic nuclear polarization of water. J Am Chem Soc (2011) 1.05
Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia (2004) 1.05
Molecular mechanism of mitochondrial membrane fusion. Biochim Biophys Acta (2006) 1.02
Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol (2002) 1.01
HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res (2006) 0.98
Pancreatic fistula following pancreaticoduodenectomy: clinical predictors and patient outcomes. HPB Surg (2009) 0.98
VEGF-C mediates cyclic pressure-induced endothelial cell proliferation. Physiol Genomics (2002) 0.97
Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. J Biol Chem (2003) 0.96
Regulation of endothelial cell proliferation and apoptosis by cyclic pressure. Ann Biomed Eng (2002) 0.96
Expression of connective tissue growth factor in pancreatic cancer cell lines. Int J Oncol (2007) 0.93
Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett (2012) 0.90
HGF and VEGF: a dynamic duo. Circ Res (2005) 0.88
In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res (2013) 0.87
In vitro reconstitution and preparative purification of complexes between the chemokine receptor CXCR4 and its ligands SDF-1alpha, gp120-CD4 and AMD3100. Protein Expr Purif (2006) 0.86
Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma. J Surg Res (2008) 0.85
Mice expressing SV40 T antigen directed by the intestinal trefoil factor promoter develop tumors resembling human small cell carcinoma of the colon. Mol Cancer Res (2004) 0.84
Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett (2012) 0.83
A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J Biomol Screen (2003) 0.82
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis (2010) 0.82
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer (2005) 0.82
Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother (2014) 0.82
Medical students' and residents' clinical and educational experiences with defensive medicine. Acad Med (2012) 0.82
Initiation of transcription of the MUC3A human intestinal mucin from a TATA-less promoter and comparison with the MUC3B amino terminus. J Biol Chem (2003) 0.80
N-glycosylation is required for the surface localization of MUC17 mucin. Int J Oncol (2003) 0.80
Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase. Bioorg Med Chem Lett (2004) 0.80
Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation (2010) 0.79
IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J (2002) 0.79
Sub-millisecond chain collapse of the Escherichia coli globin ApoHmpH. J Phys Chem B (2013) 0.79
Receptor-mediated basic fibroblast growth factor signaling regulates cyclic pressure-induced human endothelial cell proliferation. Endothelium (2005) 0.78
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer (2015) 0.78
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation. J Biomol Screen (2004) 0.76
No easy answers on vibration gloves. Occup Health Saf (2014) 0.75
Seven Ways to Go Back to Basics With Your Safety Program. Occup Health Saf (2016) 0.75
Severe hemorrhagic complication of talc pleurodesis for idiopathic pleural effusion. Hawaii Med J (2004) 0.75
Microcirculation down under. Trends Pharmacol Sci (2002) 0.75